Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-114820 · Präparat HOS-094169

Based on theoretical considerations, tipranavir or ritonavir concentrations might increase upon co-administration with itraconazole or ketoconazole. Voriconazole Due to multiple CYP isoenzyme Based on the known interaction No interaction study systems involved in voriconazole of voriconazole with low dose performed metabolism, it is difficult to ritonavir (see voriconazole predict the interaction with SmPC) the co-administration of tipranavir, co-administered with tipranavir/r and voriconazole low-dose ritonavir. should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. Anti-gouts Colchicine Based on theoretical A reduction in colchicine dosage No interaction study considerations, colchicine or an interruption of colchicine performed concentrations may increase upon treatment is recommended in co-administration with tipranavir patients with normal renal or and low dose ritonavir, due to hepatic function if treatment with tipranavir/ritonavir CYP3A and Aptivus/ritonavir is required (see P-gp inhibition. However a section 4.4). decrease of colchicine In patients with renal or hepatic concentrations cannot be impairment, co-administration of excluded since both tipranavir colchicine in patients on and ritonavir exhibit inducing

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) colchicine (HOS-086147) ritonavir (HOS-084521)